InvestorsHub Logo
Followers 14
Posts 2379
Boards Moderated 0
Alias Born 01/04/2011

Re: None

Wednesday, 10/02/2013 8:28:58 AM

Wednesday, October 02, 2013 8:28:58 AM

Post# of 26
Very smart move on the part of both BAT & XXII to sign an agreement to advance the two companies utilizing XXII's proprietary properties. Great things to come for those vested in both. Below from the N/R by both BAT & XXII

“This partnership with British American Tobacco, which sells product in approximately 180 countries, represents 22nd Century’s greatest growth milestone to date and an important step in the development of 22nd Century’s next generation tobacco products. BAT has always been our first choice as a partner,” stated Joseph Pandolfino, 22nd Century’s Founder and Chief Executive Officer.

Gary Nicholson, BAT’s Head of Global Leaf Research, stated that “BAT is excited to be working with 22nd Century in this area of developing technology. This work is part of BAT’s ongoing Research & Development activities relating to tobacco products.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering or plant breeding. 22nd Century owns or is the exclusive licensee of 112 issued patents in 78 countries plus an additional 38 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and tobacco harm reduction products in development. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BTI News